Current evidence shows apotential for cardiovascular benefits with SGLT2 inhibition that is consistentacross the spectrum of ejection fraction, age, New York Heart Association (NYHA)functional class, natriuretic peptide levels and diabetes status. This evidence concerns the gene SLC5A2 and diabetes mellitus.